The size of LDL-lipoprotein particles among patient after acute stroke

Czech version

Authors: A. Dukát ¹; S. Oravec ¹; P. Gavornik ¹; M. Wawruch ²; P. Sabaka ¹; D. Baláž ¹; L. Mistríková ³
Authors‘ workplace: II. interná klinika Lekárskej fakulty UK a UNB Bratislava, Slovenská republika, prednosta doc. MUDr. Ľudovít Gašpar, CSc. ¹; Ústav farmakológie a klinickej farmakológie Lekárskej fakulty UK Bratislava, Slovenská republika, prednostka prof. MUDr. Viera Kristová, CSc. ²; Východoslovenský ústav srdcových a cievnych chorôb Košice, Slovenská republika, predseda predstavenstva Ing. Eduard Adamčík ³
Published in: Vnitř Lék 2012; 58(7 a 8): 199-201
Category: 60th Birthday prof. MUDr. Miroslav Souček, CSc.

Overview

Introduction:
Acute stroke represents the severe state both for the patient as well as for the physician. Poor outcome with residual handicap brings the problems both for the family and for the society and the therapy and follow-up is cost expensive.

Patients and methods:
50 consecutive patients with acute stroke were admitted to the acute care unit at the internal medicine department. During acute care blood sample was examined with Lipoprint method to evaluate their lipid parameters. Size of LDL particles spectrum (LDL 1–7), before starting the drug treatment were measured.

Results:
Atherogenic profile was detected in more than three quarters of the stroke patients comparing to the controls. Presence of atherogenic smalldense LDL particles significantly differs among stroke patients to the healthy controls.

Conclusion:
Early hypolipidemic treatment among patients with acute stroke is recommended in order to lower their high cardiovascular risk.

Key words:
stroke – lipoproteins – LDL-cholesterol

Sources

1. Austin MA, King MC, Vranizan KM et al. Atherogenic lipoproteine phenotype. A proposed marker for coronary heart disease risk. Circulation 1990; 82: 495–506.

2. Van J, Pan J, Charles MA et al. Atherogenic lipid phenotype in a general group of subjects. Arch Pathol Lab Med 2007; 131: 1679–1685.

3. Superko HR. Advanced Lipoprotein Testing and Subfraction Are Clinically Useful. Circulation 2009; 119: 2383–2395.

4. Sacks FM, Campos H. Clinical review 163: Cardiovascular endocrinology: Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal. J Clin Endocrin Metabol 2003; 88: 4525–4532.

5. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. Q J Med 2006; 99: 1–14.

6. Endres M, Heuschmann PU, Laufs U et al. Primary prevention of stroke: blood pressure, lipids, and heart failure. Eur Heart J 2011; 32: 545–552. doi: 10.1093/eurheart/ehq472.

7. O’Donnell MJ, Xavier D, Liu L et al. INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorhagic stroke in 22 countries: a case-control study. Lancet 2010; 376: 243–249.

8. Oravec S. Nová laboratórno-medicínska pomoc v diagnostike dyslipoproteinémií a kardiovaskulárnych ochorení. Identifikácia LDL podskupín. Med Milit Slov 2006; 8: 28–32.

9. Oravec S. Den drohenden Herztod erkennen – und vermeiden. Der Mediziner 2010; 4: 6–7.

10. Assmann G, Cullen P, Schulte H. Non-LDL-related dyslipidaemia and coronary risk: a case-control study. Diab Vasc Dis Res 2010; 7: 204–212.

11. Appelros P, Nydevik I, Vitanen M. Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year. Stroke 2003; 34: 122–126.

12. Landray MJ, Edmunds E, Lisawhee FL et al. Abnormal low-density lipoprotein subfraction profile in patients with untreated hypertension. QJM 2002; 95: 165–171.

13. Oravec S, Gavorník P, Čaprnda M et al. Lipoproteínový profil séra pri novozistenej artériovej hypertenzii. Úloha aterogénnych lipoproteínov v patogenéze ochorenia. Vnitř Lék 2010; 56: 967–971.

14. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 1994; 5: 395–403.

15. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43: 1363–1379.

16. Shoji T, Hatsuda S, Tsuchikura S et al. Small denses low-density lipoprotein cholesterol concentration and carotid atherosclerosis. Atherosclerosis 2009; 202: 582–588.

17. Rosolová H, Petrlová B, Šimon J et al. Makroaskulární a mikrovaskulární komplikace u diabetu 2. typu. Vnitř Lék 2008; 54: 229–237.

18. Češka R, Krutská L, Zlatohlávek L et al. Komplexní léčba kardiovaskulárního rizika. Vnitř Lék 2010; 59: 839–844.